Evidence map›Paper›PMID 24317040›Full record

ArticleNature immunology2014

High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3.

Dominic De Nardo, Larisa I Labzin, Hajime Kono, Reiko Seki, Susanne V Schmidt, Marc Beyer, Dakang Xu, Sebastian Zimmer, Catharina Lahrmann, Frank A Schildberg and 17 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 261 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
261citing papers in PubMed, 1 pooled it
29.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

261 citing papers in PubMed, 1 synthesis or guideline pooled it, 455 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Neutrophils and leukocytes in acute ischemic stroke: Traditional markers for predicting clinical outcomes.Dusunen adam : Bakirkoy Ruh ve Sinir Hastaliklari Hastanesi yayin organi · 2026
    Article
  4. Observational
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

201 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 7 institutions in 4 countries.

Dominic De Nardo1] Institute of Innate Immunity, University Hospitals, Biomedical Centre, University of Bonn, Bonn, Germany. [2].
Larisa I Labzin1] Institute of Innate Immunity, University Hospitals, Biomedical Centre, University of Bonn, Bonn, Germany. [2].
Hajime KonoDepartment of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Reiko SekiDepartment of Clinical Laboratory Science, Teikyo University Faculty of Medical Technology, Tokyo, Japan.
Susanne V SchmidtLife and Medical Sciences Institute, University of Bonn, Bonn, Germany.
Marc BeyerLife and Medical Sciences Institute, University of Bonn, Bonn, Germany.
Dakang Xu1] Monash Institute of Medical Research, Monash University, Melbourne, Victoria, Australia. [2] Institute of Ageing Research, Hangzhou Normal University School of Medicine, Hangzhou, China.
Sebastian ZimmerDepartment of Medicine/Cardiology, University of Bonn, Bonn, Germany.
Catharina LahrmannDepartment of Medicine/Cardiology, University of Bonn, Bonn, Germany.
Frank A SchildbergInstitutes of Molecular Medicine and Experimental Immunology, University of Bonn, Bonn, Germany.
Johanna VogelhuberInstitute of Innate Immunity, University Hospitals, Biomedical Centre, University of Bonn, Bonn, Germany.
Michael KrautLife and Medical Sciences Institute, University of Bonn, Bonn, Germany.
Thomas UlasLife and Medical Sciences Institute, University of Bonn, Bonn, Germany.
Anja KerksiekInstitute for Clinical Chemistry and Clinical Pharmacology, University of Bonn, Bonn, Germany.
Wolfgang KrebsLife and Medical Sciences Institute, University of Bonn, Bonn, Germany.
Niklas BodeDepartment of Medicine/Cardiology, University of Bonn, Bonn, Germany.
Alena GrebeInstitute of Innate Immunity, University Hospitals, Biomedical Centre, University of Bonn, Bonn, Germany.
Michael L FitzgeraldLipid Metabolism Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Nicholas J HernandezLipid Metabolism Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Bryan R G WilliamsMonash Institute of Medical Research, Monash University, Melbourne, Victoria, Australia.ORCID 0000000249691151
Percy Knolle1] Institutes of Molecular Medicine and Experimental Immunology, University of Bonn, Bonn, Germany. [2] Institute of Molecular Immunology, Technical University of Munich, Munich, Germany.
Manfred Kneilling1] Department of Dermatology, Eberhard Karls University, Tuebingen, Germany. [2] Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tuebingen, Germany.
Martin RöckenDepartment of Dermatology, Eberhard Karls University, Tuebingen, Germany.
Dieter LütjohannInstitute for Clinical Chemistry and Clinical Pharmacology, University of Bonn, Bonn, Germany.
Samuel D WrightCardiovascular Therapeutics, CSL Limited, Parkville, Australia.
Joachim L Schultze1] Life and Medical Sciences Institute, University of Bonn, Bonn, Germany. [2].
Eicke Latz1] Institute of Innate Immunity, University Hospitals, Biomedical Centre, University of Bonn, Bonn, Germany. [2] Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA. [3] German Center for Neurodegenerative Diseases, Bonn, Germany. [4].
University of Bonn · DEHarvard University · USMonash University · AUTeikyo University · JPUniversity of Tübingen · DECSL (Australia) · AUUniversity of Massachusetts Chan Medical School · US

Funding

HDL prevention of cholesterol crystal inflammation in HIV diseaseR01HL112661 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI FITZGERALD, MICHAEL LEO, LATZ, EICKE · 2012 to 2016
$3.1M
Inflammasome activation by cholesterol crystalsR01HL093262 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LATZ, EICKE · 2009 to 2013
$2.0M
NHLBI NIH HHS 1R01HL093262NHLBI NIH HHS 1R01HL112661NHLBI NIH HHS R01 HL093262NHLBI NIH HHS R01 HL112661
6 · The paper itself

Abstract

High-density lipoprotein (HDL) mediates reverse cholesterol transport and is known to be protective against atherosclerosis. In addition, HDL has potent anti-inflammatory properties that may be critical for protection against other inflammatory diseases. The molecular mechanisms of how HDL can modulate inflammation, particularly in immune cells such as macrophages, remain poorly understood. Here we identify the transcriptional regulator ATF3, as an HDL-inducible target gene in macrophages that downregulates the expression of Toll-like receptor (TLR)-induced proinflammatory cytokines. The protective effects of HDL against TLR-induced inflammation were fully dependent on ATF3 in vitro and in vivo. Our findings may explain the broad anti-inflammatory and metabolic actions of HDL and provide the basis for predicting the success of new HDL-based therapies.

Indexed as

Activating Transcription Factor 3AnimalsAnti-Inflammatory Agents, Non-SteroidalAtherosclerosisCells, CulturedCholesterolChromatin ImmunoprecipitationCytokinesFemaleGene Expression ProfilingHigh-Throughput Nucleotide SequencingHumansInflammationLipoproteins, HDLMacrophage ActivationMacrophagesActivating Transcription Factor 3Anti-Inflammatory Agents, Non-SteroidalAtf3 protein, mouseCholesterolCytokinesLipoproteins, HDLToll-Like Receptor 4

Identifiers

PMID24317040
PMCPMC4009731
OpenAlexW2161241326

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.